CSL shares: 1 number that investors shouldn't ignore

This one number has me rethinking a CSL investment.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, one of the biggest pieces of news on the ASX so far this week has been the blockbuster earnings of healthcare giant CSL Ltd (ASX: CSL). CSL delivered its full-year results for FY 2026 yesterday. And boy, did the markets grab them (and plenty of CSL shares) and run.

By the end of yesterday's session, the CSL share price had rocketed a massive 17.25% for its best day in 20 years.

As we covered yesterday, there were a lot of lukewarm numbers in this ASX 200 healthcare stock's latest report. The company reported total revenues of US$15.89 billion for the year ended 30 June 2026. That was down 1% year on year. Underlying net profits after tax dropped 2% to US$3.1 billion.

A number of one-off costs and impairments drove CSL to a statutory net loss after tax of US$2.6 billion.

However, as my Fool colleague Mark discussed yesterday, it seems that the unbridled optimism we have seen for CSL shares this week has stemmed from its optimistic guidance for FY 2027 and beyond.

CSL told investors to expect underlying net profits after tax growth of around 5% over FY27. This indicates a return to form is on the cards for a company that repeatedly dazzled investors for the decade leading up to 2020, before a series of events tanked the company's fortunes.

Hopefully, CSL can deliver this turnaround. But now, I want to focus on one metric that has caught my eye in CSL's latest numbers.

Woman flexes muscles after donating blood.

Image source: Getty Images

CSL shares surge despite a dividend hold

That metric is the final dividend that CSL will pay out in October. Yesterday, CSL revealed that this dividend will be worth US$1.60 per share. Coupled with April's interim dividend of US$1.30 per share, the company is set to dole out a total of US$2.92 in dividends per share in 2026.

That metric is significant because it marks only the second time that CSL will not be delivering a dividend hike to its shareholders. In fact, the last time that CSL didn't increase its year-on-year payouts was in 2022, largely thanks to the aftermath of the pandemic. You'd have to go back at least another decade to find any more instances of a dividend hold from this company.

This is a personal disappointment for me. I bought CSL shares many years ago, in part thanks to its strong history of dividend growth. As such, I was rather dismayed to see another hold on CSL's 2026 payout. A company's dividend growth is, in my view, one of the most vital indicators of a company's health. It is difficult to fudge and provides a sharp insight into the health of a company. Not to mention the fact that ASX shares that consistently grow their dividends over time tend to be market beaters.

Now, CSL has been upfront about its challenges for a while now. So this hold isn't really a surprise. But it is still something I didn't want to see. That's why I'll be watching the payouts that this company declares next year like a hawk.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why are Telix Pharmaceuticals shares charging higher today?

A key approval is good news for this drug developer.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

Telix Pharmaceuticals’ US FDA approval for Pixclara is a first for glioma imaging, expanding its precision medicine offerings.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

CSL shares just fell 5% after a strong rally. Is the recovery losing steam?

Can CSL’s improving outlook justify its higher share price?

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Healthcare Shares

Higher or lower: Where are CSL shares going next?

The biotech giant has been on a tear. Is it too late to invest? Let's find out.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

ASX healthcare shares are 39% higher since June. Are you missing out?

Healthcare stocks endured a long slump before the sector pivoted three months ago.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

EchoIQ shares just crashed 48%. What happens now?

One regulatory letter, half the market cap.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

CSL shares are up 90%. How much higher can they go?

CSL’s recovery could deliver more upside or another sharp reversal.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

Why has this ASX biotech fallen nearly 50% today?

A knockback for a key approval has rocked this company.

Read more »